Japan Seen By Lilly Head As Ripe For Sales Despite Patient Decline
This article was originally published in PharmAsia News
Executive Summary
Japan's pharmaceutical market is seen by U.S.-based Eli Lilly & Co.'s chief as a potential growth market for healthcare that translates to drug sales